| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,206 | 0,296 | 17:16 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BENCHMARK HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 16.01. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.01.2026 | 460 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 16.01.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.01.2026ISIN NameCA91831M1059 VR... ► Artikel lesen | |
| 18.08.25 | XFRA 31B: AUSSETZUNG/SUSPENSION | 303 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBENCHMARK HLDGS... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 38,145 | -6,07 % | Bayer auf dem Prüfstand: Was die Lösung des Glyphosat-Streits für die Aktie bedeutet | Bayer hofft auf eine Lösung des Glyphosat-Rechtsstreits bis 2026. Was bedeutet das für die Aktie? Bayer hat in den verganngenen zwölf Monaten eine beeindruckende Aktienperformance von rund 90 Prozent... ► Artikel lesen | |
| NOVO NORDISK | 30,940 | -3,82 % | Neue Studiendaten von Novo Nordisk werden an den Märkten als eine herbe Niederlage angesehen und der Aktienkurs rutscht im hohen Tempo ab | Novo Nordisk bekommt den Konkurrenzdruck vor allem in den USA schon seit einer ganzen Weile zu spüren. Wegovy verliert dort mehr und mehr an Bedeutung, da der Wirkstoff Tirzepatid von Mitbewerber Eli... ► Artikel lesen | |
| GSK | 24,470 | -1,85 % | GSK kauft kanadische 35Pharma für 950 Millionen US-Dollar | DJ GSK kauft kanadische 35Pharma für 950 Millionen US-Dollar
Von Sarah Sloat
DOW JONES--GSK hat die Übernahme des Biopharma-Unternehmens 35Pharma für 950 Millionen US-Dollar vereinbart. 35Pharma... ► Artikel lesen | |
| INNOCAN PHARMA | 4,200 | +0,96 % | Innocan Pharma Corporation: FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time | HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"),... ► Artikel lesen | |
| EYEPOINT | 15,500 | 0,00 % | EyePoint, Inc.: EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema | - Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets - - Topline data for DURAVYU in DME anticipated in 2H 2027 - WATERTOWN, Mass.... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 73,21 | -1,81 % | Edwards Lifesciences Corp - 10-K, Annual Report | ||
| NOVERIS HEALTH SCIENCES | 0,076 | +51,20 % | JJK Holdings Ltd. Acquires $7,878,792 Convertible Debenture Of Noveris Health Sciences Inc.; Filing Of Early Warning Reports By JJK Holdings Ltd. And Pioneer Garage Limited | ||
| HAPPY BELLY FOOD GROUP | 1,080 | +0,93 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces Closing of the Sale of Holy Crap Foods as it Focuses on Accelerating its QSR Businesses | Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food... ► Artikel lesen | |
| CHRISTINA LAKE CANNABIS | 0,014 | 0,00 % | Christina Lake Cannabis Corp: Christina Lake investor Milia acquires 5.03M shares | ||
| PSYCHED WELLNESS | 0,005 | 0,00 % | Psyched Wellness Ltd.: Psyched Wellness Sells Out of First Run of Calmer and Announces New Production Run | Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched" or the "Company"), a life sciences company dedicated to developing... ► Artikel lesen | |
| DAIICHI SANKYO | 15,300 | -4,08 % | Fierce Pharma Asia-China deal growth; Daiichi's new CMO; Astellas-Vir bispecific tie-up | ||
| JAZZ PHARMACEUTICALS | 160,35 | -1,60 % | Jazz Pharmaceuticals Plc Q4 Profit Climbs | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) released earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings totaled $203.45 million,... ► Artikel lesen | |
| SWEET EARTH | 0,324 | -100,00 % | Sweet Earth Holdings Corp (4): Sweet Earth clarifies info; Vesalius RTO closing delayed | ||
| H LUNDBECK | 5,130 | +1,58 % | H. Lundbeck A/S: Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026 | Key highlights
Lundbeck's total revenue grew by +13% CER[1] (+12% DKK) to DKK 24,630 million in 2025, driven primarily by strong performance in the U.S. and Europe.
United States: DKK 13,287 million... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,570 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results | Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA (gepirone) extended-release... ► Artikel lesen |